The Starpharma Holdings Ltd (ASX: SPL) share price is in focus today as the company reported a 145% jump in full-year revenue to $12 million and reduced its reported loss by 25% to $7.5 million.
What did Starpharma report?
- Revenue rose 145% to $12.0 million (FY25: $4.9 million), mainly from the Genentech licence agreement.
- Reported loss improved to $7.5 million, down from $10.0 million last year.
- Closed FY26 with $11.0 million in cash; post-year-end capital raising added $30 million to strengthen funding.
- Research and product development spending was $11.1 million (FY25: $8.4 million), after R&D tax incentive.
What else do investors need to know?
Starpharma strengthened its balance sheet after the reporting period, raising $30 million through a well-supported entitlement offer. This extends its funding runway into FY28, giving the company greater flexibility to advance its pipeline programs.
The company has continued to invest in its DEP® technology, with particular progress on its lead radiopharmaceutical asset, DEP® HER2-Lutetium, and next-generation oncology candidates. New and existing strategic partnerships further reinforce its commercial and research initiatives.
What did Starpharma management say?
Chief Executive Officer Cheryl Maley said:
During FY26, we significantly advanced our lead radiopharmaceutical asset, DEP® HER2-Lutetium, executed new strategic partnerships and strengthened existing ones, and further validated the broad potential of DEP® with a focus on targeted oncology treatments. We thank our shareholders for their continued support throughout the year. Our focus remains on building long-term shareholder value through the development of a pipeline of targeted oncology therapies enabled by our DEP® technology. The team is committed to executing on the milestones ahead and translating our scientific and commercial progress into meaningful outcomes for patients and shareholders.
What’s next for Starpharma?
Looking ahead, Starpharma is focused on advancing its clinical and preclinical DEP® pipeline, including further development of the DEP® HER2-Lutetium asset in targeted oncology. Management says the recently strengthened cash position supports the group’s research programs and continued progress of its key partnerships.
The company aims to deliver long-term value for shareholders by progressing its innovative dendrimer-based therapies, with a particular emphasis on expanding its presence in oncology and strengthening its commercial relationships.
Starpharma share price snapshot
Over the past 12 months, Starpharma shares have surged more than 500%, significantly outpacing the All Ordinaries Index (ASX: XAO).
The post Starpharma: FY26 earnings reveal strong revenue growth and improved loss appeared first on The Motley Fool Australia.
Should you invest $1,000 in Starpharma right now?
Before you buy Starpharma shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Starpharma wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Arena REIT faces leasing challenge after Edge Early Learning enters administration
- DUG Technology scores US$9.3m software and HPC contract
- Down 56%: Has the market lost interest in Life360 shares?
- Inflation falls again, but could the RBA still raise interest rates?
- 3 reasons I’d buy the NDQ ETF now
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.